BTIG Research initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $28.00

Jefferies initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $16.00

Guggenheim upgraded Jade Biosciences from Neutral to Buy and set a new price target of $14.00

Wedbush initiated coverage of Jade Biosciences with a rating of Outperform and set a new price target of $17.00

Stifel initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $19.00

TD Cowen initiated coverage of Jade Biosciences with a rating of Buy and set a new price target of $10.00

4 - Jade Biosciences, Inc. (0001798749) (Issuer)

4 - Jade Biosciences, Inc. (0001798749) (Issuer)

3 - Jade Biosciences, Inc. (0001798749) (Issuer)

4 - Jade Biosciences, Inc. (0001798749) (Issuer)

8-K - Jade Biosciences, Inc. (0001798749) (Filer)

S-1 - Jade Biosciences, Inc. (0001798749) (Filer)

10-Q - Jade Biosciences, Inc. (0001798749) (Filer)

8-K - Jade Biosciences, Inc. (0001798749) (Filer)

SCHEDULE 13G/A - Jade Biosciences, Inc. (0001798749) (Subject)

SCHEDULE 13G - Jade Biosciences, Inc. (0001798749) (Subject)

8-K - Jade Biosciences, Inc. (0001798749) (Filer)

8-K - Jade Biosciences, Inc. (0001798749) (Filer)

8-A12B/A - Jade Biosciences, Inc. (0001798749) (Filer)

10-Q - Jade Biosciences, Inc. (0001798749) (Filer)

SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement with BB Biotech for a private placement financing that is expected to result in gross proceeds of approximately $45 million to the Company, before offering expenses. Pursuant to the terms of the securities purchase agreement, Jade is selling an aggregate of 3,214,286 shares of its common stock ("Common Stock") at a purchase price of $14.00 per share. The private pla

Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its potential as a best-in-class selective anti-APRIL monoclonal antibody for IgA nephropathy Initiated Phase 1 healthy volunteer study of JADE101; interim, biomarker-rich data expected in the first half of 2026 are anticipated to define dose and dose interval selection for patient trials Unveiled JADE201, a potentially best-in-class, half-life extended, afucosylated anti-BAFF receptor monoclonal antibody; first-in-human trial in rheumatoid arthritis expected to begin in the first half of 2026 with pot

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today presented two posters for JADE101, its investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2025. JADE101 is designed to selectively inhibit APRIL, a key driver of pathogenic IgA production in IgAN, a progressive autoimmune disease that frequently leads to end-stage kidney disease over a pati

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade"), (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Wedbush Rewind ASN Conference 2025 | November 10, 2025Fireside Chat: Monday, November 10 at 12:40 p.m. ETStifel Healthcare Conference | November 11–13, 2025Presentation: Wednesday, November 12 at 4:00 p.m. ETTD Cowen Immunology & Inflammation Virtual Summit | November 12-13, 2025Presentation: Thursday, November 13 at 3:00 p.m. ETJefferies Global Healthcare Conference - London | November 18–20, 202

Presentations to highlight JADE101's preclinical safety profile and translational framework guiding its clinical development in IgA nephropathyJADE101 is an investigational, potentially best-in-class disease-modifying anti-APRIL monoclonal antibody, with a Phase 1 healthy volunteer study underway SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it will present new preclinical safety and translational data for JADE101, its lead investigational candidate for immunogl

JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less frequent subcutaneous dosing JADE201's high affinity binding and extended half-life enabled dose-dependent BAFF receptor occupancy and sustained B cell depletion in non-human primatesFirst-in-human trial in rheumatoid arthritis expected to begin in the first half of 2026; potential for broad opportunity across multiple autoimmune diseases validated by BAFF-R biologyCompany to host conference call and webcast today at 8:00 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia,

SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $135 million to the Company, before placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including Janus Henderson Investors, Fairmount, RA Capital Management, Marshall Wace,

Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trialsJADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic profile preclinically, supporting the potential for patient-friendly subcutaneous dosing every eight weeks or longerInterim, biomarker-rich Phase 1 healthy volunteer data are expected in the first half of 2026, and are anticipated to define dose and dosing interval selection based on biomarker responses associated with optimal clinical activity in IgAN patients SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("the Company" or "Jade"), (N

SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade"), (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Cantor Global Healthcare Conference (September 3–5, 2025)Fireside Chat: Tuesday, September 3 at 3:20 p.m. ETStifel Virtual Immunology and Inflammation Forum (September 15–16, 2025)Fireside Chat: Tuesday, September 16 at 1:00 p.m. ET11th Annual World Medical Innovation Forum, hosted by Bank of America and Mass General Brigham (September 15–17, 2025)Panel: Immunology – Creating the Next Blockbuster

Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of JADE101 expected to begin in the third quarter of 2025, with interim, biomarker-rich data anticipated in the first half of 2026 $220.9 million cash and cash equivalents as of June 30, 2025 supports cash runway through 2027, including multiple clinical inflection points SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for aut

JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less frequent subcutaneous dosing JADE201's high affinity binding and extended half-life enabled dose-dependent BAFF receptor occupancy and sustained B cell depletion in non-human primatesFirst-in-human trial in rheumatoid arthritis expected to begin in the first half of 2026; potential for broad opportunity across multiple autoimmune diseases validated by BAFF-R biologyCompany to host conference call and webcast today at 8:00 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia,

Preclinical data highlighted JADE101's femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a differentiated pharmacokinetic and pharmacodynamic profile with deep and sustained IgA reductions and the potential to support convenient subcutaneous dosing every eight weeks or longer First-in-human trial expected to begin second half 2025; biomarker-rich interim data in healthy volunteers expected first-half 2026 to inform patient dose and schedule Company to host conference call and webcast today, June 9, 2025, at 8:00 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia, June

SAN FRANCISCO and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ("Jade") (NASDAQ:JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025. The presentation, titled "Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN," will be delivered